Newly developed signal-averaged vector-projection 187 channel electrocardiogram can evaluate the spatial distribution of repolarization heterogeneity

International Heart Journal

Volumn 49, Issue 2, 2008, Pages 153-164

  Nakai, Kenji ^a   Miyake, Fumihiko ^b   Kasanuki, Hiroshi ^c   Shoda, Morio ^c   Futagawa, Keisuke ^c   Takahashi, Atsushi ^c   Matsuyama, Yuko ^a,c   Nirei, Takashi ^d   Tsuboi, Junich ^a   Tsuboi, Junichi ^a   Okabayashi, Hitoshi ^a   Itoh, Manabu ^e   Kawata, Hiroshi ^f  

^a IWATE MEDICAL UNIVERSITY   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d Department of Dentistry Oral surgery   (Japan)

^e ICS Co Ltd   (Japan)

^f TOHOKU UNIVERSITY   (Japan)

Author keywords

Body surface mapping; Recovery time dispersion; Repolarization heterogeneity; Signal averaged ECG; Vector projection

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; ELECTRODE; FEMALE; HEART INFARCTION; HEART REPOLARIZATION; HUMAN; INTERMETHOD COMPARISON; MAGNETOCARDIOGRAPHY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; R WAVE; RELIABILITY; T WAVE; VECTORCARDIOGRAPHY; CELL MEMBRANE POTENTIAL; COMPARATIVE STUDY; HEART; HEART MUSCLE; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY;

AGED; BODY SURFACE POTENTIAL MAPPING; CARDIOMYOPATHY, DILATED; FEMALE; HEART; HUMANS; MALE; MEMBRANE POTENTIALS; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIUM;

EID: 45549084116     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.49.153     Document Type: Article

References (24)

1. Food and Drug Administration, HHS. International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhyflimic Drugs; availability. Notice. Fed Regist 2005; 70: 61134-5.
2. Darpo B, Nebout T, Sager PT. Clinical evaluation of QT/QTc prolongation and proarrhyffimic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E 14 guideline. J Clin Pharmacol 2006; 46: 498-507.
3. Ramanathan C, Ghanem RN, Jia P, Ryu K, Rudy Y. Noninvasive electrocardiographic imaging for cardiac electrophysiology and arrhythmia. Nat Med 2004; 10: 422-8.
4. Ramanathan C, Jia P, Ghanem R, Ryu K, Rudy Y. Activation and repolarization of the normal human heart under complete physiological conditions. Proc Natl Acad Sci USA 2006; 103: 6309-14.
5. Aiba T, Inagaki M, Shimizu W, et al. Recovery time dispersion measured from 87-lead body surface potential mapping as a predictor of sustained ventricular tachycardia in patients with idiopathic ditated cardiomyopathy. J Cardiovase Electrophysiol 2000; 11: 968-74.
6. Taccardi B, Punske BB, Lux RL, et al. Useful lessons from body surface mapping. J Cardiovasc Electrophysiol 1998; 9: 773-6.
7. Nakai K, Izumoto H, Kawazoe K, et al. Three-dimensional recovery time dispersion map by 64-channel magnetocardiography may demonstrate the location of a myocardial injury and heterogeneity of repolarization. Int J Cardiovasc Imaging 2006; 22: 573-80.
8. Nakai K, Tsuboi J, Okabayashi H, et al. Development of a signal-averaged vector-projected 187-channel high-resolution electrocardiogram for the evaluation of the spatial location of high frequency potentials and abnormal ventricular repolarization. Int Heart J 2007; 48: 701-13.
9. Frank E. The image surface of homogenous torso. Amer Heart J 1954; 47: 757-68.
10. Frank E. General theory of heart-vector projection. Circ Res 1954; 2: 258-70.
11. MacGorman DR and Rust WD. The Electrical Nature of Storms. ed. New York, Oxford University Press; 1998.
12. Indik JH, Pearson EC, Fried K, Woosley RL. Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval. Heart Rhythm 2006; 3: 1003-7.
13. Nakai K, Oka T, Okabayashi H, et al. Three-dimensional spectral map of atrial fibrillation by a 64-channel magnetocardiogram. J Electrocardiol. (in press) Available at: http//www.ncbi.nlm.nih.gov/ pubmed/17884079?dopt=Abstract
14. Lux RL, Green LS, MacLeod RS, Taccardi B. Assessment of spatial and temporal characteristics of ventricular repolarization. J Electrocardiol 1994; 27: 100-5.
15. Xia Y, Kongstad O, Hertervig E, et al. Activation recovery time measurements in evaluation of global sequence and dispersion of ventricular repolarizaton. J Electrocardiol 2005; 38: 28-35.
16. Antzelevitch C. Modulation of transmural repolarization. Ann NY Acad Sci 2005; 1047: 314-23.
17. Antzelevitch C, Shimizu W, Yan GX, et al. The M cell: its contribution to the ECG and to normal and abnormal electrical function of the heart. J Cardiovasc Electrophysiol 1999; 10: 1124-52.
18. Akar FG, Yan GX, Antzelevitch C, Rosenbaum DS. Unique topographical distribution of M cells underlies reentrant mechanism of torsade de pointes in the long-QT syndrome. Circulation 2002; 105: 1247-53.
19. Shimizu W, Antzelevitch C. Cellular and ionic basis for T-wave alternans under long-QT conditions. Circulation 1999; 99: 1499-507.
20. Fish JM, Di Diego JM, Nesterenko V, Antzelevitch C. Epicardial activation of left ventricular wall prolongs QT interval and transmural dispersion of repolarization: implications for biventricular pacing. Circulation 2004; 109: 2136-42.
21. Medina-Ravell VA, Lankipalli RS, Yan GX, et al. Effect of epicardial or biventricular pacing to prolong QT interval and increase transmural dispersion of rcpolarization: does resynchronization therapy pose a risk for patients predisposed to long QT or torsade de pointes? Circulation 2003; 107: 740-8.
22. Shah RR. Drugs, QTc interval prolongation and final ICH E14 guideline: an important milestone with challenges ahead. Drug Saf 2005; 28: 1009-28.
23. Kligfield P, Hancock EW, Helfenbein ED, et al. Relation of QT interval measurements to evolving automated algorithms form different manufacturers of electrocardiographs. Am J Cardiol 2006; 98: 88-92.
24. De Ponti F, Poluzzi E, Montanaro N. Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus. Eur J Clin Pharmacol 2001; 57: 185-209.